ArticleBMC endocrine disorders2025
Postoperative hungry bone syndrome in primary hyperparathyroidism: risk factors and outcomes at a South African tertiary centre.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHungry bone syndrome (HBS) is a complication after parathyroidectomy (PTX) for primary hyperparathyroidism (PHPT), with variable prevalence worldwide. Data on predictors and outcomes are limited. This study assessed the prevalence, risk factors, and outcomes of HBS after PTX for PHPT.
methodsA retrospective review of patients undergoing PTX for PHPT (2003–2023) at Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa. HBS was defined as hypocalcaemia (corrected serum calcium < 2.1 mmol/l) lasting > 4 days post-PTX with normal or elevated intact parathyroid hormone (iPTH). Clinical, biochemical, radiological data and hospital stay were recorded.
resultsOf 117 patients (86.4% female; 71,8% symptomatic) included in this analysis, HBS developed in 20.4% (n:24). Compared with the no-HBS group (n = 93), HBS patients were younger, leaner, and more likely to have osteoporosis or osteitis fibrosa cystica (OFC). They had higher preoperative iPTH (162.8 [104–208.7] vs. 23.1 [15.6–37.5] pmol/L, P < 0.001) and ALP (696 [308.5–1323.5] vs. 111.5 [88.0–134.2] U/L, P < 0.0001), with lower 25-OH vitamin D. Hospital stay was longer (19.5 [11.0–31.2] vs. 4.0 [3.0–4.0] days, P < 0.0001). ROC analysis identified iPTH > 121 pmol/L (Sn 73.9%, Sp 100%) and ALP > 302 IU/L (Sn 78.3%, Sp 98.9%) as cut-points for HBS. In multivariate analysis, independent predictors were OFC (OR 7.7, 95%CI 1.5–40.6; P = 0.016) and iPTH > 121 pmol/L (OR 100.5, 95%CI 4.6–2225.8; P = 0.004).
conclusionHBS remains a relevant postoperative complication in PHPT, particularly in patients with advanced skeletal disease. Elevated preoperative iPTH levels and OFC may serve as useful markers for risk stratification. These indicators can assist in guiding perioperative management and optimising patient care. HBS prolonged the hospital stay, highlighting its clinical significance and implications for healthcare resource utilisation. Early identification of high-risk patients is therefore crucial to inform perioperative strategies and improve surgical outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.